✨ Free AI Report
CDT Equity Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research CDT Equity Inc.
Company Research

CDT Equity Inc.: Business Overview, Financials & Competitive Analysis

CDT Equity is a data-driven biopharmaceutical company focused on identifying, enhancing, and monetising high-potential therapeutic assets through a combination of artificial intelligence, solid-form chemistry, and str...

Analyst-debate audio for CDT Equity Inc.

AskCyborg analysts argue the bull and bear cases for CDT Equity Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Weak

Cyborg Score thesis

Early-stage asset repositioning platform with differentiated IP strategy but acute liquidity and execution challenges reflected...

Read the full analyst-debate transcript →
Industry Biotechnology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 5, 2026
AI-Verified Research
30+ Page Report

Get the Latest CDT Equity Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

CDT Equity Inc. Overview

Pro stress-test →

CDT Equity is a data-driven biopharmaceutical company focused on identifying, enhancing, and monetising high-potential therapeutic assets through a combination of artificial intelligence, solid-form chemistry, and strategic partnerships. The Company's model is centred on value creation through intellectual property and out-licensing, rather than traditional capital-intensive drug development.

Strategic Profile

Pro stress-test →

CDT identifies clinically validated or underutilised pharmaceutical assets and enhances them through proprietary solid-form and cocrystallization technologies, generating new compositions of matter with the potential for up to 20 years of additional patent protection. The company operates as a lean platform leveraging AI and chemical expertise to reposition existing compounds rather than pursuing expensive in-house development.

Competitive Landscape

Pro stress-test →

CDT operates in the clinical-stage specialty biopharmaceutical space, focused on developing pharmaceutical products that meet unmet medical needs. Competitors include larger biopharmaceutical companies with clinical-stage pipelines, biotech platforms focusing on drug repositioning, and AI-driven drug discovery firms. CDT's differentiation centers on proprietary solid-form and cocrystallization technologies for patent life extension.

Industry Context

CDT Equity Inc. operates in Biotechnology.

Key facts

Founded: 2019 · Headquarters: Cambridge, United Kingdom · Employees: 4 · Revenue: Estimated $0-2M; early-stage platform with limited commercial revenue; primary value from IP portfolio and Sarborg equity stake · Market cap: $23.0M (as of August 31, 2026)

What the analysts stress-tested

The top findings that survived the multi-agent debate for CDT Equity Inc..

  • As of August 31, 2026, CDT had approximately $23.0 million market cap but reported stockholders' equity of approximately $103 million as of Q2 2026, indicating significant book-to-market ratio gap reflecting investor skepticism on asset realization.
  • CDT's pipeline includes AZD1656, a glucokinase activator in Phase II trials for autoimmune disorders including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant, demonstrating early-stage clinical validation of repositioned assets.

Recent developments

Material events tracked by the AskCyborg corpus.

  • September 2026Sarborg IP expansion announcement highlighting quantum computing applications for drug discovery
  • September 2026Trading halt and news pending on September 28, 2026
  • +1 moreTrack every material event for CDT Equity Inc. as it happens. Explore monitoring →
Get alerted when CDT Equity Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Recursion PharmaceuticalsComputational biology for rare disease drug discovery→SchrödingerPhysics-based software for molecular simulation and drug design→Relay TherapeuticsAI-powered drug discovery targeting protein dynamics→

Compare CDT Equity Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

CDT Equity Inc. operates in Biotechnology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology research →
NEW · MCP server

Ask your AI assistant about CDT Equity Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare CDT Equity Inc. and its top competitor on Cyborg Score”
“What did CDT Equity Inc. do this quarter?”
“Is CDT Equity Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does CDT Equity Inc. do?+
CDT Equity is a data-driven biopharmaceutical company focused on identifying, enhancing, and monetising high-potential therapeutic assets through a combination of artificial intelligence, solid-form chemistry, and str...
What is CDT Equity Inc.'s Cyborg Score?+
CDT Equity Inc. has a Cyborg Score of 3/10 (Weak). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are CDT Equity Inc.'s main competitors?+
Named competitors include Recursion Pharmaceuticals, Schrödinger, Relay Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full CDT Equity Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the CDT Equity Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track CDT Equity Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8CG Oncology, Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend BiotechTop companies in Biotechnology by Cyborg Score